Pharmaceuticals highlighted the significance of the FDA approval of Qfitlia, the sixth Alnylam-discovered RNAi therapeutic ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Robbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Actinium Pharmaceuticals, Inc. securities between October 31, ...

Cardiology drug and device makers will be back in the spotlight this weekend as the annual scientific meeting of the American ...

Schools, a SaaS platform for student wellbeing management, announced the launch of August Intelligence, the first AI agent designed to help schools access critical insights, streamline administrative ...

It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have lost about 30.3% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

In the last week, the United States market has stayed flat, yet it is up 7.8% over the past year with earnings forecasted to grow by 14% annually. In this environment, identifying high growth tech ...

FDA approves Sanofi's RNAi hemophilia drug fitusiran, licensed from Alnylam, to treat both hemophilia A and B by lowering ...

Spread the love Introduction The biotechnology industry continues to be at the forefront of scientific innovation, driving ...